Model-Based Strategy for 6-Mercaptopurine Treatment in Acute Lymphoblastic Leukemia Maintenance Phase: Prediction of 6-TGN and 6-MMP Concentrations to Optimize Treatment.

Key Points

• The research aims to optimize 6-mercaptopurine (6-MP) treatment in leukemia by predicting drug concentrations.
• Developed a model to predict 6-TGN and 6-MMP concentrations during treatment.
• Examined the impact of allopurinol co-treatment on 6-MP dosing.
• Conducted evaluations to assess treatment toxicity and efficacy.
• Allopurinol co-treatment reduced toxicity associated with 6-MP.
• Therapeutic efficacy was maintained at lower 6-MP doses.
• The model shows potential for clinical relevance but requires further validation.

Abstract